SK Bioscience Co Ltd
302440
Company Profile
Business description
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and development of vaccines. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further, it has several other vaccines under development and clinical trials, including a recombinant rotavirus vaccine.
Contact
310, Pangyo-ro
Bundang-gu, Gyeonggi-do
Seongnam13494
KORT: +82 220082200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,085
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
John Ternus, Apple’s hardware chief, will take up the role in September.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.40 | 50.80 | -0.56% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 26,163.24 | 324.24 | -1.22% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,585.86 | 236.69 | 0.40% |
| NZX 50 Index | 12,963.99 | 18.39 | 0.14% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,843.60 | 53.20 | -0.60% |
| SSE Composite Index | 4,106.26 | 21.18 | 0.52% |